Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

[1]  Christian Binder,et al.  Modeling absorption kinetics of subcutaneous injected soluble insulin , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  P. Brunetti,et al.  Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM , 1994, Diabetologia.

[3]  G. Mello,et al.  Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[4]  N. Murphy,et al.  Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[5]  S. Skovlund,et al.  Effect of the rapid‐acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[6]  C. Homko,et al.  Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. , 2003, Diabetes care.

[7]  F. Nicoletti,et al.  Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. , 2003, Diabetes research and clinical practice.

[8]  B. Campaigne,et al.  Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. , 2003, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[9]  L. Hansson,et al.  Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. , 2002, Diabetes research and clinical practice.

[10]  Gernot Brunner,et al.  A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. , 2002, Diabetes care.

[11]  Douglas G Altman,et al.  Meta‐analysis combining parallel and cross‐over clinical trials. I: Continuous outcomes , 2002, Statistics in medicine.

[12]  P. Cryer,et al.  Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.

[13]  B. Boehm,et al.  Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[14]  J. Holcombe,et al.  Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. , 2002, Clinical therapeutics.

[15]  P. Raskin,et al.  Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. , 2002, Diabetes care.

[16]  Douglas G Altman,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.

[17]  B. Campaigne,et al.  Effects of a Fixed Mixture of 25% Insulin Lispro and 75% NPL on Plasma Glucose during and after Moderate Physical Exercise in Patients with Type 2 Diabetes , 2002, Current medical research and opinion.

[18]  J. Subić,et al.  Insulin lispro improves postprandial glucose control in patients with diabetes mellitus. , 2002, Sbornik lekarsky.

[19]  B. Zinman,et al.  A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[20]  P. Raskin,et al.  A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. , 2001, Journal of diabetes and its complications.

[21]  J. Holcombe,et al.  Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. , 2001, Pediatrics.

[22]  N. Tajima,et al.  Comparison between Insulin Aspart and Soluble Human Insulin in Type 1 Diabetes(IDDM) Patients Treated with Basal-Bolus Insulin Therapy : Phase III Clinical Trial in Japan , 2001 .

[23]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[24]  J. Komulainen,et al.  Post‐prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[25]  H. Arnqvist,et al.  Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF‐I and IGFBP‐1 in type 1 diabetes , 2001, Clinical endocrinology.

[26]  B. Frier,et al.  Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin , 2001, Diabetes/metabolism research and reviews.

[27]  P. Mattioli,et al.  Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. , 2001, Diabetes, nutrition & metabolism.

[28]  D. Bruttomesso,et al.  Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. , 2001, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[29]  B. Bode,et al.  Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. , 2001, Diabetes care.

[30]  I. Olkin,et al.  Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement , 2000, Oncology Research and Treatment.

[31]  A. Lindholm,et al.  Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[32]  Lawrence A Leiter,et al.  Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. , 2000, Diabetes care.

[33]  U. Johansson,et al.  Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. , 2000, Diabetes & metabolism.

[34]  E. Group.  A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy , 2000 .

[35]  E. Gale,et al.  A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[36]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[37]  S. Heller,et al.  Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. , 1999, Diabetes care.

[38]  L. Jovanovič,et al.  Metabolic and immunologic effects of insulin lispro in gestational diabetes. , 1999, Diabetes care.

[39]  P. Roach,et al.  Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. , 1999, Diabetes care.

[40]  P. Brunetti,et al.  Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. , 1999, Diabetes care.

[41]  M. Trautmann,et al.  Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. , 1999, Clinical therapeutics.

[42]  R. Landgraf,et al.  Use of Insulin Lispro in Continuous Subcutaneous Insulin Infusion Tre a t m e n t , 1999 .

[43]  P. Home,et al.  Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. , 1998, Diabetes care.

[44]  I. Mühlhauser,et al.  Risk factors of severe hypoglycaemia in adult patients with Type I diabetes – a prospective population based study , 1998, Diabetologia.

[45]  P. Brunetti,et al.  Use of the short‐acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time‐interval injection‐meal , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[46]  R. Landgraf,et al.  Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[47]  F. Holleman,et al.  Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro , 1997, Diabetes Care.

[48]  P. Iversen,et al.  Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Clinical therapeutics.

[49]  R. Heine,et al.  Metabolic Efficacy of Preprandial Administration of Lys(B28), Pro(B29) Human Insulin Analog in IDDM Patients: A comparison with human regular insulin during a three-meal test period , 1997, Diabetes Care.

[50]  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[51]  L. Vignati,et al.  Health-Related Quality-of-Life Results From Multinational Clinical Trials of Insulin Lispro: Assessing benefits of a new diabetes therapy , 1997, Diabetes Care.

[52]  B. Zinman,et al.  Insulin Lispro in CSII: Results of a Double-Blind Crossover Study , 1997, Diabetes.

[53]  L. Vignati,et al.  Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. , 1997 .

[54]  L. Vignati,et al.  Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.

[55]  L. Vignati,et al.  Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. , 1997, Clinical therapeutics.

[56]  M. Trautmann,et al.  Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[57]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[58]  J. M. Beals,et al.  LYS(B28)PRO(B29)-HUMAN INSULIN , 1996 .

[59]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[60]  H. Chase,et al.  Pre‐meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 Diabetes , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[61]  J. Windeler,et al.  Events per person year—a dubious concept , 1995, BMJ.

[62]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[63]  P. Brunetti,et al.  Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM RID=""ID="" Abbreviations: HI, Human insulin; MI, monomeric insulin; NEFA, non-esterified fatty acid; HGO, hepatic glucose production rate; , 1994 .

[64]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[65]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[66]  Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. , 1991, The American journal of medicine.

[67]  C. Binder,et al.  The relationship between symptomatic and biochemical hypoglycaemia in insulin‐dependent diabetic patients , 1990, Journal of internal medicine.

[68]  B. Zinman.  The Physiologic Replacement of Insulin , 1989 .

[69]  B. Zinman.  The physiologic replacement of insulin. An elusive goal. , 1989, The New England journal of medicine.

[70]  H. Uchino,et al.  DEPARTMENT OF INTERNAL MEDICINE , 1966 .